Innovating Works

VISMEDERI SRL

Desconocido
VIVACE: Management of avian influenza in a vaccination context While outbreaks of highly pathogenic avian influenza viruses (HPAIV) in Europe used to be rare and geographically contained, the situation h...
2024-07-08 - 2028-11-30 | Financiado
Inno4Vac: Innovations to accelerate vaccine development and manufacture VISMEDERI SRL participó en un H2020 H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado
INDIGO: Effective and Affordable Flu Vaccines for the World VISMEDERI SRL participó en un H2020 H2020-SC1-BHC-2018-2020 Despite the availability of flu vaccines for decades, influenza is still an important disease in both developing and developed countries wit...
2019-12-13 - 2025-03-31 | Financiado
PRONKJEWAIL: Protecting patients with enhanced susceptibility to infections VISMEDERI SRL participó en un H2020 H2020-MSCA-COFUND-2015 The Microbes in Health and Disease research programme at the University Medical Center Groningen (UMCG) proposes the Doctoral Training Progr...
2016-03-31 - 2021-08-31 | Financiado
BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety VISMEDERI SRL participó en un FP6 BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado
ADITEC: Advanced Immunization Technologies VISMEDERI SRL participó en un FP7 Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious...
Financiado
BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety VISMEDERI SRL participó en un FP7 BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.